<DOC>
	<DOCNO>NCT01947608</DOCNO>
	<brief_summary>Novartis-sponsored , open-label , multi-center , interventional ETP provide LDK378 patient ALK ( + ) NSCLC , pre-treated ALK inhibitor ; except country ALK inhibitor approve available . The protocol evaluate safety LDK378 patient ALK ( + ) NSCLC .</brief_summary>
	<brief_title>Expanded Treatment Protocol With LDK378 ALK ( + ) NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Inclusion Criteria ( patient eligible inclusion early treatment protocol meet follow criterion ) : 1 . Histologically cytologically confirm diagnosis NSCLC demonstrate ALK positivity assess approved FISH test ( Abbott Molecular Inc ) , use Vysis breakapart probe ( define 15 % positive tumor cell ) ; Ventana IHC test . If documentation ALK positivity available , test confirm ALK positivity must perform accord criterion , use new tumor biopsy obtain prior first dose ETP treatment ( LDK378 ) . 2 . Stage IIIB IV NSCLC patient document disease progression enrollment , qualify access LDK378 clinical trial . 3 . Age 18 year old time inform consent . 4. WHO performance status 03 . 5 . Patients pretreated ALK inhibitor locally advance metastatic NSCLC . Patients may enrol without prior exposure ALK inhibitor country ALK inhibitor approve available . Exposure prior chemotherapy require . 6 . Patients must recover toxicity relate prior anticancer therapy grade ≤ 2 ( CTCAE v 4.03 ) , provide concomitant medication give prior initiation treatment LDK378 . Exception criterion : patient grade alopecia allow enter treatment . 7 . The following laboratory criterion meet : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Hemoglobin ( Hgb ) ≥ 8 g/dL Platelets ≥ 75 x 109/L Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , except patient Gilbert 's syndrome may include total bilirubin ≤ 3.0 x ULN direct bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) &lt; 3.0 x ULN , except patient liver metastasis , include AST &lt; 5 x ULN ; alanine transaminase ( ALT ) &lt; 3.0 x ULN , except patient liver metastasis , include ALT &lt; 5 x ULN . Calculated measured creatinine clearance ( CrCL ) ≥ 30 mL/min 8 . Patient must follow laboratory value follow laboratory value correct supplement within normal limit screen : Potassium ≥ LLN Magnesium ≥ LLN Phosphorus ≥ LLN Total calcium ( correct serum albumin ) ≥ LLN 9 . Written inform consent ETP protocol must obtain prior screen procedure . If consent express writing , must formally document witnessed , ideally via independent trusted witness . 10 . Willingness ability comply schedule visit , treatment plan , laboratory test ETP procedure . Exclusion Criteria ( patient eligible ETP must meet follow criterion ) : 1 . Patients know hypersensitivity excipients LDK378 ( microcrystalline cellulose , mannitol , crospovidone , colloidal silicon dioxide magnesium stearate ) . 2 . Patients symptomatic CNS metastasis neurologically unstable require increase dos steroid within 1 week prior ETP entry manage CNS symptom . 3 . Prior therapy LDK378 . 4 . The patient le 5 halflives prior ALK inhibitor target therapy ( adequate washout ) without recovery treatment toxicity ≤ grade 1 pretreatment level . 5 . Chemotherapy investigational therapy ≤ 3 week prior start LDK378 treatment recover side effect treatment toxicity ≤ grade 2 pre treatment toxicity level , exception liver cardiac function must ≤ grade 1 . 6 . Patients receive thoracic radiotherapy lung field ≤ 4 week prior start study treatment patient recover radiotherapyrelated toxicity . For anatomic site ( include radiotherapy thoracic vertebra rib ) radiotherapy ≤ 2 week prior start LDK378 treatment recover radiotherapyrelated toxicity . Palliative radiotherapy bone lesion ≤ 2 week prior start LDK378 treatment allow . 7 . Major surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) within 4 week prior ( 2 week resection brain metastasis ) start LDK378 treatment recover side effect procedure . Videoassisted thoracic surgery ( VATS ) mediastinoscopy count major surgery , patient enrol ETP ≥ 2 week procedure . 8 . Presence history malignant disease NSCLC diagnose and/or require therapy within past 3 year . Exceptions exclusion include follow : completely resect basal cell squamous cell skin cancer , completely resect carcinoma situ type . 9 . Patients known history extensive disseminate bilateral interstitial fibrosis interstitial lung disease , include history pneumonitis , hypersensitivity pneumonitis , interstitial pneumonia , obliterative bronchiolitis , clinically significant radiation pneumonitis ( i.e . affect activity daily live require therapeutic intervention ) . 10 . Patient clinically significant , uncontrolled heart disease and/or recent cardiac event ( within 6 month ) , : unstable angina within 6 month prior screen ; myocardial infarction within 6 month prior screen ; history document congestive heart failure ( New York Heart Association functional classification IIIIV ) ; uncontrolled hypertension define Systolic Blood Pressure ( SBP ) ≥ 160 mm Hg and/or Diastolic Blood Pressure ( DBP ) ≥ 100 mm Hg , without antihypertensive medication initiation adjustment antihypertensive medication ( ) allow prior screening ; ventricular arrhythmia ; supraventricular nodal arrhythmia control medication ; cardiac arrhythmia control medication ; correct QTc &gt; 450 msec use Fridericia correction screen ECG 11 . Impaired GI function GI disease may alter absorption LDK378 inability swallow five LDK378 capsule daily 12 . Ongoing GI adverse event &gt; grade 2 ( e.g . nausea , vomit , diarrhea ) start ETP . 13 . Receiving medication meet one follow criterion discontinue least 1 week prior start treatment LDK378 duration ETP participation ( see Appendix 1 : Tables 141 , Table 142 , Table 143 , Table 144 ) : Medication know risk prolong QT interval induce Torsades de Pointes ( please refer http : //www.azcert.org/medicalpros/druglists/druglists.cfm ) Strong inhibitor strong inducer CYP3A4/5 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Medications low therapeutic index primarily metabolize CYP3A4/5 , CYP2C8 and/or CYP2C9 ( please refer http : //medicine.iupui.edu/flockhart/table.htm http : //www.druginteractioninfo.org ) Therapeutic dose warfarin sodium ( Coumadin ) coumadinderived anticoagulant . Anticoagulants derive warfarin allow ( eg , dabigatran , rivaroxaban , apixaban ) . Unstable increase dos corticosteroid enzymeinducing anticonvulsive agent herbal supplement 14 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 15 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month last dose study treatment . In case use oral contraception , woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g. , age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior screen . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . 16 . Sexually active male unless use condom intercourse take drug 3 month last dose study treatment . Male patient 3 month father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>